Saw Palmetto for Prostate Disorders



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2003 Mar 15;67(06):1281-1283.

Saw palmetto is an herbal product used in the treatment of symptoms related to benign prostatic hyperplasia. The active component is found in the fruit of the American dwarf palm tree. Studies have demonstrated the effectiveness of saw palmetto in reducing symptoms associated with benign prostatic hyperplasia. Saw palmetto appears to have efficacy similar to that of medications like finasteride, but it is better tolerated and less expensive. There are no known drug interactions with saw palmetto, and reported side effects are minor and rare. No data on its long-term usage are available. The herbal product also has been used to treat chronic prostatitis, but currently there is no evidence of its efficacy.

Saw palmetto, also known as Serenoa repens or Sabal serrulatum, is an herb that is most commonly used to treat problems related to benign prostatic hyperplasia (BPH). The medicinal element of saw palmetto is taken from the partially dried ripe fruit of the American dwarf palm tree, which is indigenous to the coastal regions of the southern United States, from the Carolinas and Florida to California.

BPH is a nearly universal result of the aging process in men. As the prostate gland enlarges, it can cause both obstructive and irritative symptoms; however, the size of the prostate gland is not predictive of the symptoms that patients experience.

Saw palmetto is widely used in other countries; for example, it is used in 50 percent of treatments for BPH in Italy and in 90 percent of such treatments in Germany.1 The active part of the plant is the sterols and free fatty acids found in the berry. The particular solvent used in the extraction process affects the resulting formulation of the product. The most widely studied form of saw palmetto is Permixon, which uses the solvent hexane; other formulations have used ethanol, methanol, and liquid carbon dioxide as solvents. Historically, saw palmetto was administered with nettle root and pumpkin seeds, and some modern formulations include these elements.

It is unclear which components are the most active, and the mechanism of action is not fully understood. Some of the mechanisms proposed include anti-inflammatory activity,2 blocked conversion of testosterone to dihydrotestosterone (DHT),3,4 and prostate epithelial involution similar to effects noted with the use of finasteride (Proscar).5

Relief of Symptoms

Treatments for BPH can be evaluated by their effect on symptoms such as diminished urine stream, post-void dribbling, overflow incontinence, and urinary retention, or by less useful measures such as urine flow rate, changes in prostate size, and residual volume. In a Cochrane Review, investigators conducted a meta-analysis of randomized controlled studies comparing saw palmetto with placebo or other drugs.6 [Evidence level A: systematic e r view of randomized controlled trials RCTs] The review combined the results of 21 trials with durations of four to 48 weeks. The 21 studies included a total of 3,139 men with a mean age of 65 years (range: 40 to 88 years). According to the International Prostate Symptom Scale, these men had moderate symptoms, with an average urologic score of 14.4 points out of a possible 35 (moderate BPH symptoms range from eight to 19).6 In the 13 studies that reported symptom scores, saw palmetto improved symptom scores, individual symptoms, and flow measures more than placebo. Patients and physicians were more likely to report improvement in symptoms with saw palmetto treatment than with placebo. In the12 studies that reported nocturia results, saw palmetto reduced nocturia by 25 percent compared with placebo.

In two studies, saw palmetto and finasteride had similar positive effects on urinary symptom scores and peak urine flow. Adverse effects caused by saw palmetto were mild and infrequent and comparable to side effects from placebo. Withdrawal rates among patients receiving placebo, saw palmetto, and finasteride were 7.1, 8.9, and 9.0 percent, respectively.

Results similar to those in the Cochrane Review were produced by a more recent r e view.7 [Evidence level A: RCTs] Saw palmetto has not been compared with surgical approaches in the treatment of BPH. Saw palmetto is also widely used for treatment of chronic prostatitis, although scientific evidence of benefit is lacking.

Contraindications, Adverse Effects, and Interactions

The primary side effect occurring in humans is gastrointestinal distress, which is mild and can be minimized by taking saw palmetto with food. Saw palmetto is believed to be quite safe, although formal toxicology studies have not been completed. One study8 found no mutagenic or teratogenic effects in rats and dogs that were fed saw palmetto in a dosage of 2 g per kg daily for six months, and this dosage was well tolerated. No clinically relevant changes in laboratory parameters have been found in human clinical trials.9

There has been some concern that saw palmetto could mask prostate cancer by lowering prostate-specific antigen (PSA) levels. However, a randomized study10 of more than 1,000 patients did not demonstrate this effect on PSA levels. The same study showed that finasteride decreased PSA levels by 41 percent.

Dosage

Clinical studies have used a dosage of 160 mg twice daily or 320 mg once daily of a lipophilic extract containing 80 to 90 percent of the volatile oil. A daily dosage of 480 mg was not found to be any more effective in a six-month study of dosages.8 Teas are not considered to be effective because they do not contain the volatile oils. The whole berries can be used at the recommended dosage of 1 to 2 g daily.11 As with most herbal medications, the recommended dosage for saw palmetto may vary because of the lack of standardization of such products in the United States.

Herbal medication products that are commonly available for purchase may not be the same as those used in clinical studies and, therefore, may not produce the same results. There are no known drug interactions with saw palmetto. The cost for typical saw palmetto products ranges from $6 to $20 per month at a dosage of 160 mg twice daily.

Final Comment

Saw palmetto is an effective treatment for the symptoms of BPH. It appears to be as effective as finasteride and is better tolerated, less expensive, and less likely to decrease PSA levels. No research has evaluated the effect of saw palmetto on long-term outcomes in patients with BPH. Table 1 reviews the efficacy, safety, tolerability, and cost of saw palmetto.

TABLE 1

Key Points About Saw Palmetto

Efficacy

Reducing symptoms of BPH: effective

Treatment of chronic prostatitis: evidence lacking

Adverse effects

Mild gastrointestinal distress: infrequent

Not known to interfere with the diagnosis of prostate cancer

Interactions

No known drug interactions

Dosage

Varies; most studies have used 160 mg twice daily or 320 mg once daily

Cost

$6 to $20 per month, depending on brand, for a dosage of 160 mg twice daily

Bottom line

Safe herbal medicine; effective for treatment of symptoms of BPH


BPH = benign prostatic hyperplasia.

TABLE 1   Key Points About Saw Palmetto

View Table

TABLE 1

Key Points About Saw Palmetto

Efficacy

Reducing symptoms of BPH: effective

Treatment of chronic prostatitis: evidence lacking

Adverse effects

Mild gastrointestinal distress: infrequent

Not known to interfere with the diagnosis of prostate cancer

Interactions

No known drug interactions

Dosage

Varies; most studies have used 160 mg twice daily or 320 mg once daily

Cost

$6 to $20 per month, depending on brand, for a dosage of 160 mg twice daily

Bottom line

Safe herbal medicine; effective for treatment of symptoms of BPH


BPH = benign prostatic hyperplasia.

The Authors

ANDREA E. GORDON, M.D., is on the faculty of the Harrisburg Family Practice Residency, Harrisburg, Pa. She received her medical degree from Jefferson Medical College in Philadelphia. Dr. Gordon completed a family practice residency program at the University of Connecticut, Hartford, and a fellowship in family practice faculty development at St. Margaret Memorial Hospital, Pittsburgh, Pa. She is currently enrolled in an integrative medicine fellowship at the University of Arizona, Tucson.

ALLEN F. SHAUGHNESSY, PHARM.D., is director of research and associate director of the Harrisburg Family Practice Residency. He completed his doctorate and fellowship training at the Medical University of South Carolina, Charleston.

Address correspondence to Andrea E. Gordon, M.D., Harrisburg Family Practice Residency, 2501 N. Third St., Harrisburg, Pa., 17110-2098 (e-mail: agordon@pinnaclehealth.org). Reprints are not available from the authors.

The authors indicates that they do not have any conflicts of interest. Source of funding: none reported.

REFERENCES

1. Di Silverio F, D'Eramo G, Lubrano C, Flammia GP, Sciarra A, Palma E, et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol. 1992;21:309–14.

2. Lowe FC, Ku JC. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology. 1996;48:12–20.

3. Briley M, Carilla E, Roger A. Inhibitory effect of Permixon on testosterone 5a-reductase activity of the rat ventral prostate. Br J Pharmacol. 1984;83(suppl):401P.

4. Marks LS, Hess DL, Dorey FJ, Macairan ML, Cruz Santos PB, Tyler VE. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology. 2001;57:999–1005.

5. Marks LS, Partin AW, Epstein JI, Tyler VE, Simon I, Macairan ML, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol. 2000;163:1451–6.

6. Wilt T, Ishani A, MacDonald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;3:CD001423.

7. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology. 2001;58:960–4.

8. Small JK, Bombardelli E, Morazzoni P. Serenoa repens (Bartram). Fitoterapia. 1997;68:99–113.

9. Plosker GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging. 1996;9:379–95.

10. Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate. 1996;29:231–40.

11. Saw palmetto monograph. The Natural Medicines Comprehensive Database. www.naturaldatabase.com. Accessed December, 2002.



Copyright © 2003 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article